☆ 4.8 Meeting Abstract

Solti-1716. Targeting with pembrolizumab plus paclitaxel non-luminal by PAM50 hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK4/6 inhibitor treatment (TATEN trial)

CANCER RESEARCH (2022)

Get Full Text
Add to Collection

Journal

CANCER RESEARCH
Volume 82, Issue 4, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1538-7445.SABCS21-OT1-17-01

Keywords

-

Categories

Oncology

Funding

  1. MSD

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.